Leber Congenital Amaurosis (LCA) is a severe inherited retinal disorder that causes profound vision loss from birth or within the first few months of life. It is one of the most serious forms of childhood blindness and is characterized by early degeneration of photoreceptor cells in the retina. LCA is genetically heterogeneous, meaning it can be caused by mutations in more than 20 different genes involved in retinal development and function.
Children with LCA usually present with very poor visual responses, lack of eye contact, abnormal eye movements such as nystagmus, and extreme sensitivity to light or, in some cases, reduced response to light. Parents may notice that the child does not follow objects, has difficulty recognizing faces, or frequently presses or rubs the eyes, a behavior known as the oculodigital reflex. As the condition progresses, both rod and cone photoreceptors are affected, leading to combined loss of night vision, peripheral vision, central vision, and color perception.
LCA is a neurodevelopmental retinal disorder, meaning that the retina does not develop or function properly from early life. Conventional treatment options are extremely limited. While gene therapy is available for a small subset of patients with specific genetic mutations, most forms of LCA still have no definitive curative treatment. Current management focuses on visual rehabilitation, low-vision aids, special education support, and protective measures to improve quality of life.
Stem cell therapy offers a regenerative approach for managing retinal degeneration associated with LCA. At Stem Cell Cure India, advanced regenerative protocols are designed to support retinal cell survival, enhance neuroprotection, and improve the overall retinal microenvironment. Stem cells release growth factors, cytokines, and bioactive molecules that help reduce inflammation, improve cellular metabolism, and support remaining retinal neurons.
Although stem cells cannot fully regenerate a structurally absent or severely underdeveloped retina, they may help preserve existing retinal cells and improve functional visual responses in selected patients. The therapeutic goal is to stabilize vision, delay further degeneration, and enhance visual processing pathways that support daily functioning.
Before initiating therapy, patients undergo a comprehensive diagnostic evaluation including detailed ophthalmic examination, optical coherence tomography (OCT), electroretinography (ERG), visual evoked potentials (VEP), genetic testing when available, and systemic health assessment. These investigations help determine disease severity, retinal structure, and treatment suitability.
At Stem Cell Cure India, treatment for LCA related retinal dystrophy is individualized based on age, genetic profile, retinal status, and neurological development. Because most patients are children, special emphasis is placed on safety, ethical protocols, and long-term monitoring. Visual rehabilitation programs are often integrated with regenerative therapy to maximize functional outcomes.
Stem cell therapy for LCA represents an advanced supportive option for patients who have limited conventional treatment choices. By focusing on neuroprotection, retinal support, and functional enhancement, Stem Cell Cure India provides a scientifically guided and patient-centered approach aimed at improving visual potential and long-term quality of life for individuals affected by congenital retinal degeneration.
A severe genetic retinal disorder causing vision loss from infancy.
Some gene and stem cell therapies may help.
Yes, usually within the first few months.
They may improve retinal cell activity in selected cases.
Yes, it is genetic.
